| The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma MW Bennett, J O’Connell, GC O’Sullivan, C Brady, D Roche, JK Collins, ... The Journal of Immunology 160 (11), 5669-5675, 1998 | 441 | 1998 |
| The Fas counterattack: cancer as a site of immune privilege J O’Connell, MW Bennett, GC O’Sullivan, JK Collins, F Shanahan Immunology today 20 (1), 46-52, 1999 | 331 | 1999 |
| Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis B Sheil, J McCarthy, L O’mahony, MW Bennett, P Ryan, JJ Fitzgibbon, ... Gut 53 (5), 694-700, 2004 | 260 | 2004 |
| Immune privilege or inflammation? Insights into the Fas ligand enigma J O'Connell, A Houston, MW Bennett, GC O'Sullivan, F Shanahan Nature medicine 7 (3), 271-274, 2001 | 204 | 2001 |
| Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer MW Bennett, J O’connell, GC O’sullivan, D Roche, C Brady, J Kelly, ... Gut 44 (2), 156-162, 1999 | 193 | 1999 |
| PCR detection of Mycobacterium paratuberculosis in Crohn’s disease granulomas isolated by laser capture microdissection P Ryan, MW Bennett, S Aarons, G Lee, JK Collins, GC O’sullivan, ... Gut 51 (5), 665-670, 2002 | 181 | 2002 |
| Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer J O'Connell, MW Bennett, GC O'Sullivan, D Roche, J Kelly, K Collins, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 1998 | 172 | 1998 |
| Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor‐immune conflict JOE O'CONNELL, MW Bennett, K Nally, A Houston, GC O'SULLIVAN, ... Annals of the New York Academy of Sciences 910 (1), 178-195, 2000 | 164 | 2000 |
| Helicobacter pylori modulates lymphoepithelial cell interactions leading to epithelial cell damage through Fas/Fas ligand interactions J Wang, X Fan, C Lindholm, M Bennett, J O'Connoll, F Shanahan, ... Infection and immunity 68 (7), 4303-4311, 2000 | 151 | 2000 |
| An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer C O'donnell, A Mahmoud, J Keane, C Murphy, D White, S Carey, ... British journal of cancer 114 (1), 37-43, 2016 | 103 | 2016 |
| Introducing 3-dimensional printing of a human anatomic pathology specimen: potential benefits for undergraduate and postgraduate education and anatomic pathology practice A Mahmoud, M Bennett Archives of pathology & laboratory medicine 139 (8), 1048-1051, 2015 | 103 | 2015 |
| Microcystic/reticular schwannoma: a distinct variant with predilection for visceral locations B Liegl, MW Bennett, CDM Fletcher The American journal of surgical pathology 32 (7), 1080-1087, 2008 | 101 | 2008 |
| The Fas counterattack: a molecular mechanism of tumor immune privilege J O’Connell, MW Bennett, GC O’Sullivan, JK Collins, F Shanahan Molecular Medicine 3 (5), 294-300, 1997 | 101 | 1997 |
| Fas counter-attack–the best form of tumor defense? J O'Connell, MW Bennett, GC O'Sullivan, JK Collins, F Shanahan Nature medicine 5 (3), 267-268, 1999 | 96 | 1999 |
| Interferon‐γ sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis J O'Connell, MW Bennett, K Nally, GC O'Sullivan, JK Collins, F Shanahan Journal of cellular physiology 185 (3), 331-338, 2000 | 87 | 2000 |
| PATI: Patient accessed tailored information: A pilot study to evaluate the effect on preoperative breast cancer patients of information delivered via a mobile application NM Foley, EP O'Connell, EA Lehane, V Livingstone, B Maher, ... The breast 30, 54-58, 2016 | 85 | 2016 |
| Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression A Houston, MW Bennett, GC O'Sullivan, F Shanahan, J O'Connell British journal of cancer 89 (7), 1345-1351, 2003 | 71 | 2003 |
| Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege J O’Connell, MW Bennett, GC O’Sullivan, J O’Callaghan, JK Collins, ... Clinical Diagnostic Laboratory Immunology 6 (4), 457-463, 1999 | 69 | 1999 |
| Fas ligand upregulation is an early event in colonic carcinogenesis MW Bennett, J O'Connell, A Houston, J Kelly, GC O'Sullivan, JK Collins, ... Journal of clinical pathology 54 (8), 598-604, 2001 | 66 | 2001 |
| Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo A Houston, FD Waldron‐Lynch, MW Bennett, D Roche, GC O'Sullivan, ... International journal of cancer 107 (2), 209-214, 2003 | 45 | 2003 |
